Enfusion

Enfusion Debt/EBITDA

Delisted

Total Debt to EBITDA Ratio of Enfusion (ENFN) as of Nov 7, 2026.

Debt/EBITDA

0.00

Last updated:

Total Debt to EBITDA Ratio of Enfusion is 2024 0.00 . Total Debt to EBITDA Ratio of Enfusion was 2023 0.00 . It decreases by % lower compared to the previous year.

The Enfusion Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2019
2.00 USD
Jan 1, 2020
16.23 USD
Jan 1, 2021
0.00 USD
Jan 1, 2022
0.00 USD
Jan 1, 2023
0.00 USD
Jan 1, 2024
0.00 USD
The Enfusion Debt/EBITDA history
YEARDebt/EBITDAYoY
0.00—
0.00—
0.00—
0.00-100.00%
16.23+712.77%
2.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Enfusion Stock analysis

What does Enfusion do? Enfusion Inc. generates revenue through cloud-native multi-tenant software solutions tailored for alternative and institutional investment managers. Its core products include the Portfolio Management System (PMS), Order and Execution Management System (OEMS), Accounting/General Ledger System, and Enfusion Analytics System, which collectively enable real-time investment decision-making. The company serves investment managers who require integrated systems for the full investment lifecycle, with PMS constructing and rebalancing portfolios while generating a real-time investment book of record, and OEMS facilitating electronic trade order communication for portfolio managers, traders, compliance teams, and analysts. The company's solution integrates technology-powered managed services to drive insights and control over investment operations. Enfusion's end-to-end functionality supports the entire investment process, from portfolio construction to trade execution, with PMS and OEMS operating in tandem to provide a seamless workflow. Investment managers across alternative and institutional segments purchase these integrated systems to enhance operational efficiency and decision-making capabilities. Enfusion's software is designed to serve the full investment lifecycle, with its systems integrated to provide a unified platform for portfolio management, order execution, accounting, and analytics. The company's revenue model is based on delivering these comprehensive solutions to investment managers who rely on real-time data and integrated workflows to manage their operations effectively. Enfusion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Enfusion stock

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Enfusion since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Enfusion with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Enfusion

All Key Metrics — Enfusion